Lilly Acquires Phase III Intranasal Glucagon from Locemia Solutions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Piper Jaffray Cuts Price Target on Eli Lilly & Co. (LLY) Following Announced Discontinuation of Evacetrapib
October 13, 2015 8:38 AM EDTPiper Jaffray reiterated an Overweight rating on Eli Lilly (NYSE: LLY), and cut the price target to $118.00 (from $120.00), following the company's announced discontinuation of its CETP inhibitor evacetrapib. LLY's stock fell by 7.8% following the announcement.
Analyst Richard Purkiss commented, "Yesterday, LLY's stock fell by 7.8%... More
Eli Lilly & Co. (LLY) Acquires Rights to Locemia's Intranasal Glucago
October 9, 2015 4:01 PM EDTEli Lilly and Company (NYSE: LLY) and Locemia Solutions today announced Lilly has acquired worldwide rights to Locemia's intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin. Intranasal glucagon, which is currently in Phase III clinical trial testing, could be the first needle-free rescue treatment for severe hypoglycemia.
Intranasal glucagon uses a proprietary glucagon nasal powder formulation that is delivered in an emergency... More
